SLC5A2 and hydrops fetalis: The clinical, echocardiographic, and functional improvement of such patients following SGLT2 inhibitor initiation is well documented [127,128], while besides classic mechanisms considered to be cardioprotective [129], it has been recently reported that SGLT2 inhibitors, among other pathways, benefit the coronary microvasculature, which is evidently impaired in patients with HF, therefore contributing to enhanced myocardial perfusion [130].